Analysts Say Buy These Stocks: Cerner Corporation (NASDAQ:CERN), DENTSPLY International Inc. (NASDAQ:XRAY), Lumos Networks Corp. (NASDAQ:LMOS), Rosetta Genomics Ltd. (NASDAQ:ROSG)

Wall Street analysts are maintaining Buy rating on Cerner Corporation (NASDAQ:CERN) company shares.  The one year target on the name currently stands at $64.30.  The stock recently touched $51.59 and has moved in the range of $51.27 - 52.16 during the current session.  Based on a recent bid this places the stock +3.41% away from the 52-week floor of $49.89 and -31.87% away from the 52-week ceiling of $75.72.

When stocks are given “Buy” ratings by analysts, the reasons or criteria for that recommendation can greatly vary.  Typically when a stock is given this label, analysts are expecting that the stock will outperform their peers, their sector or the market over a 6 to 12 month time frame. Several factors might include near-term catalysts, future earnings growth.  Many analysts only give a Buy recommendation when they expect that the stock will yield a return of at least 5-10% over the course of a year.  Since analyst criteria and recommendation terminology can differ, we can look at consensus numbers to get a feel of overall analyst sentiment.

DENTSPLY International Inc. (NASDAQ:XRAY) has been given a consensus Buy rating by analysts on Wall Street. According to Thomson Reuters' First Call, research brokers have a one year price target of $64.29 on the stock. The stock is currently trading +7.27% away from its 200-day moving average of $57.35. Based on a recent trade, shares of DENTSPLY International Inc. are -3.04% away from the 52-week high of $63.45 and +24.33% away from the 52-week low of $49.48.

Analysts are estimating that the company will report earnings of $2.78 for the current year and $0.75 for next quarter. The stock closed the most recent trading session at $60.67.

Shares of Lumos Networks Corp. (NASDAQ:LMOS) continue to be viewed favorably by equities brokerage firms on Wall Street.  The First Call consensus which is calculated by Thomson Reuters has a $17.75 price target and Buy rating according to the covering analysts.  During today’s session the stock hit $12.04 or +1.09% from the previous close, while moving in the range of $11.03 - 12.15.

Shares of Rosetta Genomics Ltd. (NASDAQ:ROSG) continue to be viewed favorably by equities brokerage firms on Wall Street.  The First Call consensus which is calculated by Thomson Reuters has a $4.17 price target according to the covering analysts.  During today’s session the stock hit $1.17 or +5.98% from the previous close, while moving in the range of $1.15 - 1.25.  This puts the stock -72.32% away from the 52-week high of $4.48 and +74.65% away from the 52-week low of $0.71.

Exact definitions of a “Buy” rating can greatly vary depending on the equity research firm.  The consensus rating simply provides an average of those recommendations.  It's important to note that a “Buy” rating does not mean that every investor should acquire the stock. It is just a single factor among many that should be considered before making an investment decision.